The visceral (VIS) and subcutaneous (SQ) fat pads are developmentally distinct white adipose tissue depots and contribute differently to inflammation and insulin resistance associated with obesity. The basic helix-loop-helix transcriptional regulator, transcription factor 21 (TCF21), is a marker gene for white adipose tissues and is abundantly expressed in VIS-derived adipose stem cells (ASCs), but not in SQ-derived ASCs. However, TCF21's role in regulating fat depot-specific gene expression and function is incompletely understood. Here, using siRNA-mediated Tcf21 knockdowns and lentiviral gene transfer of TCF21 in mouse ASCs, we demonstrate that TCF21 is required for the VIS ASC-specific expression of interleukin 6 (IL6), a key cytokine that contributes to the proinflammatory nature of VIS depots. Concurrently, TCF21 promotes MMP-dependent collagen degradation and type IV collagen deposition through the regulation of the extracellular matrix (ECM) modifiers, matrix metalloproteinase (MMP) 2, MMP13, and tissue inhibitor of MMP1 (TIMP1), as well as collagen type IV ␣1 chain (COL4A1) in VIS ASCs. We also found that although IL6 mediates the expression of Mmp13 and Timp1 in VIS ASCs, the TCF21-dependent expression of Mmp2 and Col4a1 is IL6-independent. These results suggest that TCF21 contributes to the proinflammatory environment in VIS fat depots and to active ECM remodeling of these depots by regulating IL6 expression and MMP-dependent ECM remodeling in a spatiotemporally coordinated manner.
inflammatory tissue damage relative to SQ WAT as exemplified by increased macrophage infiltration and extracellular matrix (ECM) remodeling (3) . Among a cohort of adipokines secreted from expanding adipose tissues, the expression of interleukin-6 (IL6) from VIS WAT is associated with chronic inflammation in obesity (4) . Moreover, the level of adipose IL6 expression is correlated with the degree of insulin resistance in humans (5, 6) , suggesting a potential role for VIS WAT-derived IL6 in adipose tissue inflammation and insulin resistance associated with visceral adiposity.
Adipose tissue ECM remodeling is another key pathological process observed in obesity (7, 8) . Transcriptomic profiling of VIS and SQ WAT-derived stem cell antigen-1 (Sca1)-high adipose-derived stem cells (ASCs) demonstrates the differential expression of inflammatory cytokines, matrix metalloproteinases (MMPs), and tissue inhibitors of MMPs (TIMPs) (9) . VIS ASCs display increased expression of MMP8 and MMP13 as well as TIMP1, all of which are highly induced under inflammatory and obesogenic conditions (10 -13) . Elevated VIS ASC expression of MMP8 and MMP13 was associated with the expression of proinflammatory cytokines, including IL6 and CXCL1 (9) . Despite these observations, the transcriptional regulation underlying VIS ASC-specific expression of inflammatory cytokines and MMP/TIMP family members has not been well established.
To define the transcriptional network of VIS ASCs responsible for the co-expression of IL6 and a subset of MMPs and TIMPs, we focused on transcription factor 21 (TCF21), a basic helix-loop-helix (bHLH) transcription factor abundantly expressed in VIS ASCs but barely in SQ ASCs. A human TCF21 gene variant is associated with larger pericardial fat mass (14) , and TCF21 promotes epithelial-mesenchymal transition (EMT) of epicardial cells to cardiac fibroblasts (15) . Gene targeting of Tcf21 results in perinatal lethality of mice, demonstrating its indispensable role in organ development (16, 17) .
Even though TCF21 has been recognized as a WAT-specific marker gene (18) , its potential role in regulating VIS WATspecific inflammatory gene expression and ECM remodeling has not been fully explored. Here, we identify a novel role for TCF21 in driving the expression of IL6, as well as a subset of MMP/TIMP family members (MMP2, MMP13, and TIMP1) and type IV collagen in IL6-dependent and -independent manners. TCF21-dependent regulation of IL6 expression and ECM remodeling may contribute to the unique characteristics of visceral WAT.
Results

TCF21 is co-expressed with IL6 and specific ECM remodeling factors in visceral adipose stem cells
Our previous work showed the depot-specific transcriptomes of mouse WAT Sca1 high ASCs using whole-genome RNA-seq (9) . The gene encoding basic helix-loop-helix transcription factor Tcf21 was among the most differentially expressed; its transcript is present at high level in VIS ASCs but nearly undetectable in SQ ASCs (Fig. 1A) . TCF21 is an established regulator of epicardial fibroblast EMT and development of kidney, lung, and spleen (16, 17) ; however, its function in WAT is presently undefined.
The mRNA levels of Il6 and Timp1 were also preferentially expressed in VIS ASCs, whereas those of Mmp2 and Mmp14 were similar between ASCs of both depots (Fig. 1A) . Notably, Mmp13 transcript level in VIS ASCs was more than double the level observed in SQ ASCs (Fig. 1A) .
Real-time qPCR confirmed our RNA-seq findings, showing VIS ASC expression of TCF21 180-fold, and expression of IL6 50-fold that seen in SQ ASCs (Fig. 1B) . The mRNA analysis of human preadipocytes derived from VIS and SQ WAT revealed a similar pattern (Fig. 1C ). In agreement with gene expression, immunocytochemistry of cultured ASCs revealed nuclear TCF21 staining in VIS ASCs but not in SQ ASCs (Fig. 1D ). IL6 staining was similarly restricted to VIS ASCs and showed substantial co-expression with TCF21 among VIS WAT-derived stromal cells ( Fig. 1E ). Indeed, IL6 was detected in 89% of TCF21-positive, but only in 34% of TCF21-negative VIS WATderived vascular stromal cells ( Fig. 1E, right panel) .
Within mouse VIS (perigonadal) adipose depot, TCF21 protein was seen exclusively in cells positive for platelet-derived growth factor receptor ␣, a cell-surface marker of fibroblastadipocyte progenitors ( Fig. 1F) (19, 20) . On the contrary, TCF21 was undetectable in SQ (inguinal) depots isolated from the same animals ( Fig. 1F ). TCF21 and IL6 were expressed in the same cells specifically in VIS fat depot ( Fig. 1F ). Taken together, these data show that in WAT, TCF21 is restricted to ASCs of VIS depot and mostly co-expressed with IL6 in these cells. Genes encoding specific ECM remodeling factors, MMP13 and TIMP1, were also preferentially expressed in VIS ASCs relative to SQ ASCs.
TCF21 is necessary for IL6 expression in VIS ASCs
We hypothesized that TCF21 could transcriptionally regulate genes expressed in VIS ASCs, including IL6. To test this, we 
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examined the effect of siRNA-mediated TCF21 knockdown on IL6 transcription and protein expression in isolated mouse VIS ASCs. Two independent siRNA oligonucleotides (designed within Tcf21 coding regions) suppressed mRNA levels by 40 and 75%, respectively ( Fig. 2A ). Correspondingly, Il6 transcript levels declined to 36 and 46% of baseline ( Fig. 2B ). We next evaluated the impact of Tcf21 knockdown on levels of IL6 protein in the culture medium. Western blotting revealed progressive accumulation of IL6 protein over a 3-day culture period in control siRNA-treated group, and the time-dependent accumulation of IL6 was comparable with that of type I collagen ( Fig. 2C ). IL6 protein content was decreased in the media of VIS ASCs treated with Tcf21 siRNAs at each time point, whereas no significant effect was observed for type I collagen ( Fig. 2C ). IL6 protein was nearly undetectable in the medium of cultured SQ ASCs (Fig. 2C ). Together, these data demonstrate that Tcf21 is necessary for IL6 expression specifically in mouse VIS ASCs, and the minimal expression of Tcf21 accounts for the very low IL6 expression in SQ ASCs. Conversely, when we overexpressed human TCF21 in mouse VIS ASCs using lentiviral gene transfer, we observed that Il6 expression increased in parallel with TCF21 expression ( Fig. 2D ).
We identified multiple E-box consensus sequences (CANNTG) in the IL6 promoter region ( Fig. 2E ). We sought to determine whether TCF21 could regulate IL6 promoter activity. We examined the effect of TCF21 overexpression (Fig. S1 ) on a reconstituted IL6 promoter activity, using its 5Ј-UTR (approximately Ϫ1.5 kb), in Chinese hamster ovary (CHO) cells, which express no endogenous TCF21 (data not shown). IL6 promoter activity in CHO cells was increased 10-fold by co-expressed TCF21 (Fig.   2F ). Deletion of a putative bHLH domain (amino acids 78 -132) from TCF21 (21) significantly attenuated TCF21-dependent IL6 promoter activity ( Fig. 2F ). These results suggest that TCF21 acts as a transcriptional regulator of IL6 promoter.
TCF21 is required for the expression of collagenolytic MMPs and TIMP1 in VIS ASCs
RNA-seq identified unique expression profiles of ECM remodeling factors (MMPs and TIMPs) in mouse VIS and SQ ASCs (9) . Among collagenolytic MMPs, Mmp13 was highly expressed in VIS ASCs, whereas transcripts encoding gelatinolytic MMP2 and MMP9 were more abundant in SQ ASCs. Tcf21 knockdown by siRNA in VIS ASCs markedly suppressed MMP13 mRNA ( Fig. 3A ). On the contrary, expression of the gene encoding MMP14 (MT1-MMP), a major pericellular collagenase equally expressed in VIS and SQ ASCs ( Fig. 1A) , was unaffected by Tcf21 siRNA (Fig. 3A) . Expression of tissue inhibitor of matrix metalloproteinase-1 (Timp1), abundant in VIS ASCs but not in SQ ACSs, was suppressed by Tcf21 knockdown (Fig. 3A) . By contrast, Tcf21 siRNA treatment did not change the expression of Timp2 or Timp3, which showed no predominance in VIS ASC over SQ ASC in RNA-seq data (Fig. 3A) . VIS ASC-specific expression of Mmp8 was not impacted by Tcf21 knockdown (Fig. 3A ). Unexpectedly, Tcf21 was found to be required also for the expression of Mmp2 in VIS ASCs and to a lesser extent in SQ ASCs ( Fig. 3A and Fig. S2 ). Consistent with the effect on Mmp2 expression, Tcf21 siRNA reduced MMP2 protein level as detected by gelatin zymography (Fig. 3B ).
TCF21 is responsible for type IV collagen deposition by VIS ASCs
In cultured VIS ASCs, Tcf21 knockdown specifically reduced the expression of Col4a1 but had no impact on Col1a1 or Col3a1 (Fig. 4A ). This suggests a specific role for TCF21 in The siRNA oligonucleotides targeting Tcf21 and control siRNA were transfected to mouse VIS ASCs and cultured for 3 days. A, total RNA was extracted for RT-qPCR analysis (n ϭ 4, means Ϯ S.E.). **, p Ͻ 0.01; ***, p Ͻ 0.001; ****, p Ͻ 0.0001 by one-way ANOVA. B, to assess MMP2 activity, the media of transfected cells were changed to serum-free DMEM a day after transfection; conditioned media were collected 3 days later and subjected to gelatin zymography. This is a representative figure (n ϭ 3, means Ϯ S.E.). ****, p Ͻ 0.0001 by one-way ANOVA.
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regulation of basement membrane structure. Type IV collagen deposition by VIS ASCs detected by immunohistochemistry was not much changed with Tcf21 knockdown (Fig. 4B ). Nonetheless, whereas type IV collagen fibers appeared robust and well organized in control siRNA-treated samples, they appear diffuse and finer in Tcf21 siRNA-treated samples (Fig. 4B , high magnification). The Tcf21 knockdown also reduced the amount of degraded type I collagen products ( Fig. 4C ), suggesting that TCF21 mediates both degradation of type I collagen fibers and the deposition of a basement membrane component, type IV collagen. TCF21-dependent degradation of type I collagen was MMP-dependent, as shown by the suppression of the collagen degradation by a MMP inhibitor, GM6001 (Fig. 4D ). We next assessed the impact of TCF21 overexpression on ASC collagen deposition. Lentiviral gene transfer of TCF21 resulted in enhanced TCF21 signals in VISC ASCs and novel presence of TCF21 in SQ ASCs (Fig. S3 ). Elevated TCF21 levels markedly enhanced the deposition of type IV and I collagens in VIS ASCs (Fig. 4E ). SQ ASCs, which demonstrate a low staining of type IV collagen at baseline, also showed considerably increased deposition of type IV collagen with TCF21 overexpression (Fig. 4E ). The effect of TCF21 was collagen type-selective, and no discernable effect was observed on the level of type VI collagen ( Fig. 4E ). TCF21-dependent accumulation of type IV collagen was pronounced more in VIS ASCs than in SQ ASCs (Fig. 4E ). Not only the deposition of collagens, but also TCF21 overexpression augmented the degradation of type I collagen by VIS ASCs (Fig. 4F ). Together, these findings suggest that TCF21 actively engages in type I collagen turnover and type IV collagen deposition by VIS ASCs through the regulation of MMP activities.
IL6 is responsible for the expression of MMP13 and TIMP1 but not for collagen IV and MMP2 and ECM remodeling
Given positive regulation of IL6 by TCF21, we sought to determine whether TCF21-dependent ECM remodeling requires IL6 effector function. To test this, we incubated VIS and SQ ASCs with IL6-neutralizing antibody with and without recombinant IL6. We found that mRNA levels of Mmp13 and Timp1 were reduced in the presence of anti-IL6 antibody and that the effect was rescued by the presence of excess recombinant IL6 (Fig. 5A ). On the contrary, expression of Col4a1 and Mmp2 were unaffected by either IL6-neutralizing antibody or IL6 protein ( Fig. 5A ). To determine whether TCF21 regulates type IV collagen deposition and type I collagen degradation through IL6 and its potential effectors, i.e. MMP13 and TIMP1, VIS 
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ASCs transfected with siTcf21 or control siRNA were cultured in the presence and absence of IL6-neutralizing antibody. Despite the inhibitory effects on the expression of MMP13 and TIMP1, the presence of IL6-neutralizing antibody did not change either type IV collagen deposition or type I collagen degradation (Fig. 5B ), suggesting that TCF21 promotes collagenolytic ECM remodeling in a IL6-independent manner.
Discussion
In this report, we have demonstrated for the first time that TCF21, a bHLH transcription factor, drives the expression of IL6 concurrently of MMP2 and type IV collagen in VIS ASCs. TCF21 has been known to regulate the EMT of epicardial fibroblast progenitors (15) and to be essential for the development of the heart, kidney, and spleen (17) . Although TCF21 was recognized as a gene highly expressed in white adipose tissues (18) , its role in adipose tissue biology, particularly in WAT depot-dependent gene expression, had been unknown.
WAT actively expands in response to excess calorie intake; however, the cellular mechanisms underlying the expansion of two WAT depots, i.e. visceral and subcutaneous WAT, appear different (22, 23) . Visceral WAT expansion involves not only hypertrophy of adipocytes but ASC proliferation and adipogenesis, particularly in male mice (22, 23) . Our previous work suggests that a cohort of transcription factors along with cytokines and ECM remodeling genes are differentially expressed between VIS and SQ ASCs (9). Jeffery et al. (23) suggest that visceral WAT provides a microenvironment permissive for ASC proliferation and adipogenesis under a high-fat diet condition. Nonetheless, it is unclear whether the pro-adipogenic microenvironment of VIS WAT is conferred by paracrine cytokines, ECM molecules, or physical interaction between stromal cells and other cell types. Our data suggest that TCF21, which is specifically expressed in VIS ASCs, is responsible for the expression of IL6 along with ECM remodeling genes in VIS ASCs. It is likely that the heightened expression of IL6 coupled with type IV collagen deposition and type I collagen degradation contributes to a unique VIS WAT microenvironment permissive for inflammatory adipose tissue expansion in vivo (22, 23) .
IL6 is expressed most abundantly in adipose tissues, followed by the heart, kidney, and spleen (24) . In parallel, TCF21 expression is found not only in adipose tissues, but also in the heart, kidney, and spleen. TCF21 plays an indispensable role for the development of these organs (15) (16) (17) . Our study shows the role of TCF21 in regulating IL6 expression and ECM remodeling in white adipose tissues; however, it is conceivable that TCF21 may play a similar role in regulating IL6 expression and ECM remodeling in the vital organs, such as the heart and kidney. The potential role for TCF21 in defining pro-inflammatory environment and ECM remodeling may need to be further investigated in these organs.
The role of IL6 in obesity has been somewhat controversial. Although visceral WAT-derived IL6 is correlated with the presence of insulin resistance (4), skeletal muscles respond to IL6 favorably by improving whole-body glucose metabolism (25) . In mice, genetic loss of IL6 paradoxically increases the risk of age-dependent obesity (26) , insulin resistance, and steatohepatitis (27) . Our findings suggest that a bHLH transcriptional factor, TCF21, is essential for IL6 expression in VIS ASCs. The expression of TCF21 and IL6 in visceral WAT did not change during a short-term, high-fat diet challenge in mice (data not shown); however, macrophages infiltrating WAT in chronic obesity express high levels of IL6 in the late stage of high-fat diet-induced obesity (28) . Despite these findings, the specific contribution of stromal versus macrophage-derived IL6 to insulin resistance in the early and late stages of obesity remains unclear. Our study has not addressed whether TCF21-dependent expression of stromal IL6 expression is metabolically beneficial or detrimental for glucose metabolism in obesity. Nonetheless, because TCF21 and IL6 are expressed in VIS WAT under both physiological and obesogenic conditions, it is likely that TCF21-dependent IL6 expression and ECM remodeling may play an active role in defining visceral WAT function in both development and obesity.
Experimental procedures
Animals C57BL/6J and 129SvEv male mice 8 -12 weeks of age were purchased from the Jackson Laboratory (Bar Harbor, ME) and Taconic (Rensselaer, NY), respectively. The animals were housed in a pathogen-free environment with 12-h light-dark cycle and free access to food and water. Animal studies and procedures were approved by the University of Michigan Institutional Animal Care and Use Committee. 
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Isolation of Sca1 high ASCs
Mouse primary vascular stromal cells were isolated as described previously (9) . VIS and SQ WATs were isolated, minced, and digested by 5 mg/ml type 3 collagenase (Worthington Biochemical Corp., Freehold, NJ) in Hanks' balanced salt solution with calcium and magnesium (Invitrogen/Thermo Fisher Scientific) at 37°C for 20 min. DMEM containing 10% FBS was added to the cell suspension to inactivate collagenase, and then cells were passed through a 100-m cell strainer. After centrifugation for 10 min at 1,500 rpm (412.5 ϫ g), the pellet was resuspended in 5 ml of distilled water for 30 s to lyse red blood cells. After adding growth medium (DMEM containing 10% FBS, 20 mM glutamine, 100 units/ml penicillin, 100 units/ml streptomycin, and 250 ng/ml amphotericin B), the cell suspension was passed through a 100-m cell strainer again and centrifuged for 10 min at 1,500 rpm and seeded onto a culture plate. The cultured primary cells were applied to MACS separator (Miltenyi Biotec, Auburn, CA) to enrich for Sca1 high ASCs as previously reported (9, 29) .
Cell culture
Isolated mouse ASCs and human primary preadipocytes from VIS and SQ WAT (Lonza, Fair Lawn, NJ) were cultured in DMEM containing 10% FBS.
Immunostaining
Cultured cells were fixed in 4% paraformaldehyde/PBS and permeabilized with 0.2% Triton X-100 in PBS for 20 min. To stain extracellular collagen, this permeabilization was skipped, and detergents were excluded during all subsequent steps. Adipose tissue was fixed in 4% paraformaldehyde/PBS overnight and cut into small pieces (Ͻ2 mm square). After permeabilization in 0.5% Triton X-100 in PBS for 3 h, tissue chunks were washed three times with 0.1% Triton X-100 in PBS and blocked with 10% nonimmune goat serum in PBS for 1 h. Rabbit anti-TCF21 antibody (catalog no. 32981, 1:100, Abcam, Cambridge, MA), rat anti-mouse IL6 antibody (catalog no. MAB406, 1:100, R&D Systems, Minneapolis, MN), mouse anti-platelet-derived growth factor receptor ␣ antibody (catalog no. sc-398206, 1:100, Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit anti-collagen IV antibody (catalog no. 600-401-106, 1:100, Rockland Immunochemicals Inc., Limerick, PA), rabbit anticollagen I (catalog no. 600-401-103, 1:200, Rockland Immunochemicals Inc.), rabbit anti-collagen VI (catalog no. 600-401-108, 1:100, Rockland Immunochemicals Inc.), and C1,2C (staining degraded collagen) (catalog no. 50-1035, 1:200, IBEX Pharmaceuticals Inc., Montreal, Canada) were used for immunostaining. After a subsequent wash in PBS, the samples were incubated with donkey Alexa Fluor 594 anti-rabbit IgG (catalog no. A11072, 1:1000, Invitrogen), donkey Alexa Fluor 488 antirabbit IgG (catalog no. A11070, 1:1000, Invitrogen) or donkey Alexa Fluor 488 anti-mouse IgG (catalog no. A11017, 1:1000, Invitrogen), Alexa Flour 488 phalloidin (Invitrogen) for F-actin, and DAPI (Invitrogen) for nuclear staining. The samples were mounted in ProLong Gold Antifade Reagent (Invitrogen), and fluorescent images were obtained with Nikon A1si confocal microscope and NIS element 4.0 software (Tokyo, Japan). Signal intensity in five images from each sample was quantified using Image (National Institutes of Health, Bethesda, MD). Each experiment was repeated at least twice.
siRNA treatment, lentiviral transduction, IL6/IL6-neutralizing antibody treatment, and gene expression analysis
For TCF21 knockdown, ASCs were transfected with control siRNA (siControl), CCUGCGGUAGAUGAACCAUUCA-CAA, siRNA against Tcf21 (siTcf21) #1, CCUCAGCGAUGU-AGAAGACCUUCAA, or siTcf21 #2, CCGGCAAACCAGAG-AATGACCTGAA. Briefly, siRNA (10 nM) was incubated with Lipofectamine RNAiMAX (Invitrogen) in Opti-MEM (Gibco/ Thermo Fisher Scientific) and added to cell suspension at the beginning of cell culture as per the manufacturer's recommendation. For TCF21 overexpression, lentivirus carrying TCF21 gene in pLenti-GIII-CMV-GFP-2A-Puro vector (Applied Biological Materials Inc., Richmond, Canada) was transduced with 8 g/ml Polybrene (American Bioanalytical, Natick, MA) for 8 h twice. GM6001 (10 M final, Millipore-Sigma) was added to culture for 2 days. VIS and SQ ASCs were incubated in the presence or absence of 100 ng/ml IL6-neutralizing antibody (catalog no. MAB406, R&D systems) and 30 ng/ml recombinant mouse IL6 (Cell Signaling) in serum-free DMEM supplied 1 g/ml. RNA was extracted from cultured cells using RNeasy mini kit (Qiagen) and subjected to reverse transcription with SuperScript II (Invitrogen). cDNA samples were then subjected to qPCR by using either Power SYBR green or Universal Taq-Man Mastermix in StepOnePlus (Applied Biosystems/Thermo Fisher Scientific). Relative cDNA quantities were normalized to the expression of a housekeeping gene, 36B4 (Rplp0), and are shown as fold change relative to control. Sequences of primers and TaqMan probes are shown in Table S1 .
Western blotting
Conditioned medium from cultured cells was mixed with 4ϫ Laemmli sample buffer (Bio-Rad) and heat denatured for 5 min at 95°C. Protein samples were then separated by standard SDS-PAGE in 13% acrylamide gel followed by transfer to nitrocellulose membrane (Bio-Rad). Primary antibodies recognizing anti-IL6 antibody (catalog no. 12912, 1:1000, Cell Signaling Technology, Danvers, MA), anti-Mmp13 antibody (catalog no. IM78, 1:400, EMD Millipore, Billerica, MA), anti-mCherry antibody (catalog no. 632543, 1:1000, TaKaRa Clontech), and anti-TCF21 antibody (1:1000) were used for immunoblotting. The membranes were treated with horseradish peroxidaseconjugated secondary antibodies: anti-rabbit IgG antibody (catalog no. 170 -6515, 1:5000, Bio-Rad) and anti-mouse IgG antibody (catalog no. 170 -6516, 1:5000), and chemiluminescent signal was developed using ECL Western blotting substrate (Pierce/Thermo Fisher Scientific) for detection with FluorChem M (Proteinsimple, Santa Clara, CA).
Promoter activity assay
Synthesized human IL6 promoter region (Ϫ1479 to ϩ21) was cloned into pGL3-basic plasmid (Promega, Madison, WI). Synthesized human TCF21 ORF (GenBank TM accession no. NM_198392) was cloned into pmCherry-C1 (TaKaRa Clontech, Kyoto, Japan). Amino acids 78 -132 in TCF21 were predicted as basic helix-loop-helix by BLAST and was eliminated TCF21 in adipose IL6 and ECM remodeling by inverse PCR using 5Ј-GGGGAAGCAGCAGATCCT-GGCTAACGACA-3Ј (forward) and 5Ј-CCAGGATCTGC-TGCTTCCCCTCCTGGCTGA-3Ј (reverse) primers and a QuikChange site-directed mutagenesis kit (Agilent Technologies, Palo Alto, CA). mCherry-tagged protein expression was confirmed by transfecting the plasmid into COS7 cells followed by Western blotting with the cell lysates. For promoter activity assay, 500 ng of pmCherry-TCF21 and 500 ng of pGL3-IL6 promoter or their empty vector were transfected together with 20 ng of pRL-TK Renilla luciferase plasmid (Promega) and 2.5 l of Lipofectamine 2000 (Invitrogen) into CHO cells in each well of 12-well plate. Two days later, firefly and Renilla luciferase activity was assayed by using a dual-luciferase reporter assay system (Promega) and a Synergy NEO microplate reader (BioTek Instruments, Inc., Winooski, VT).
Gelatin zymography
Conditioned medium from cultured cells was mixed with 2ϫ sample buffer (125 mM Tris, pH 6.8, 20% glycerol, 4% SDS, and 0.005% bromphenol blue) and incubated for 10 min at room temperature. Then the samples were separated by 10% SDS-PAGE gel containing 1 mg/ml gelatin (type A from porcine skin; Sigma). The gels were incubated in 2.5% Triton X-100 for 30 min at room temperature and then in developing buffer (50 mM Tris, 200 mM NaCl, 6.7 mM CaCl 2 , and 0.02% Brij35 (Sigma)) at 37°C overnight. Collagenolytic bands were visualized by 0.5% Coomassie R-250 (Sigma) dissolved in 5% methanol and 10% acetic acid.
Statistical analysis
All data were statistically analyzed using Student's t test or paired t test, one-way ANOVA with post hoc multiple comparison by Tukey's procedure, or two-way ANOVA with post hoc multiple comparison by Sidak's procedure as specified in the figure legends. 
